Background/Aims: Liddle syndrome (LS) is a rare autosomal dominant disease caused by mutations in genes coding for epithelial sodium channel (ENaC) subunits. The aim of this study was to identify the mutation responsible for the LS in an extended Chinese family. Methods: DNA samples from the proband with early-onset, treatment-resistant hypertension, and hypokalemia and 19 additional relatives were all sequenced for mutations in exon 13 of the β-ENaC and γ-ENaC genes, using amplification by polymerase chain reaction and direct DNA sequencing. Results: Genetic testing of exon 13 of SCNN1B revealed duplication of guanine into a string of 3 guanines located at codon 602. This frameshift mutation is predicted to generate a premature stop codon at position 607, resulting in truncated β-ENaC lacking the remaining 34 amino acids, including the crucial PY motif. Among a total of 9 participants with the identical mutation, different phenotypes were identified. Tailored treatment with amiloride was safe and effective in alleviating disease symptoms in LS. No mutation of SCNN1G was identified in any of the examined participants. Conclusions: We report here a family affected by LS harboring a frameshift mutation (c.1806dupG) with a premature stop codon deleting the PY motif of β-ENaC. Our study demonstrates that the earlier LS patients are diagnosed by genetic testing and treated with tailored medication, the greater the likelihood of preventing or minimizing complications in the vasculature and target organs.
Introduction
Elevated blood pressure (BP) is currently the single largest contributor to the global burden of disease and to global mortality [1] . In contrast to the case in essential hypertension, in only a minority of patients with secondary hypertension, an underlying hereditary cause is responsible for the elevated BP [2] . Monogenic hypertension syndromes are a particular subset of secondary hypertension, involving hypertensive disorders that follow Mendelian inheritance patterns due to causative single-gene mutations [3] .
Liddle syndrome (LS, OMIM #177200) is an uncommon and autosomal dominant form of monogenic hypertension which was first described by Liddle et al. [4] . Its typical clinical characteristics include salt-sensitive hypertension with early penetrance, hypokalemia, suppression of both plasma renin and aldosterone secretion, and metabolic alkalosis. Whereas the presentation of LS varies somewhat even within families carrying the same mutation. The effective treatment includes a low-salt diet and epithelial sodium channel (ENaC) inhibitors, such as amiloride and triamterene, but not spironolactone therapy [5] . ENaC, composed of α, β, and γ subunits, plays an important role in BP control by regulating of sodium and water reabsorption [6] . SCNN1A, SCNN1B, and SCNN1G each encode one of the 3 ENaC subunits [7] . Gain-of-function mutations in these genes lead to LS [8] [9] [10] . Clinically, many patients with LS are misdiagnosed and develop severe complications at an early age, due to the absence of genetic evidence that supports the diagnosis of LS [11] . Genetic testing, regarding as a rapid and accurate tool, is highly advisable for patients with a clinical suspicion of LS.
In this study, we characterized a Chinese family with LS, caused by a frameshift mutation (c.1806dupG) in SCNN1B, which generated a new stop codon at position 607. Genotypephenotype analysis showed heterogeneity among the family members, especially in terms of the existence of hypokalemia. Genetic diagnosis and tailored medicine were beneficial for combating LS, avoiding a series of severe complications associated with malignant hypertension and hypokalemia.
Methods

Subjects
The proband (III-16), a 35-year-old male, was hospitalized at the hypertension center of Fuwai Hospital, Beijing, China, for the suspicion of LS due to early-onset and treatmentresistant hypertension, spontaneous and persistent hypokalemia, and low plasma renin concentration (PRC). A total of 19 at-risk family members ( Fig. 1 ) of the proband agreed to undergo clinical evaluation, biochemical examination, and genetic testing.
Clinical and Biochemical Evaluation
The proband underwent echocardiography; computed tomography (CT) of the kidneys, adrenal glands, renal arteries, coronary artery, and aorta; and cardiac magnetic resonance imaging during hospitalization. After maintaining a standing position for 2 h, all participants underwent biochemical measurement of PRC and plasma aldosterone concentration (PAC) at Fuwai Hospital by chemiluminescence immunoassay using the LIAISON ® Direct Renin kit (DiaSorin S.p.A, Vercelli, Italy) and the LIAISON ® Aldosterone kit (DiaSorin Inc., Stillwater, MN, USA). Other biochemical examinations were performed using standard methods.
Genetic Testing
Sequencing of exon 13 of both SCNN1B and SCNN1G is highly advisable in patients with early-onset hypertension [12] . Genomic DNA was extracted from peripheral blood leucocytes using the QIA Amp DNA Blood Mini kit (QIAGEN, Hilden, Germany) in accordance with standard protocols. SCNN1B (GenBank accession number NM_000336) and SCNN1G (GenBank accession number NM_001039) are closely associated with LS [13] . Apart from α-ENaC C479R [14] , all of the other mutations are clustered within exon 13 of either SCNN1B or SCNN1G [15] . Amplification of exon 13 of SCNN1B and SCNN1G was conducted by polymerase chain reaction using 2 gene-specific primer pairs, in accordance with the work of Yang et al. [11] (β-subunit primer pair: 5′-CAAGAATCACCTCCCAGGAAGC-3′, 5′-GTGATTCTACAGAGCCCTTGGC-3′); γ-subunit primer pair (5′-CTTGGGAATCAGGGTTCCTGTG-3′, 5′-AAGCAGGCTTTTTGGTCAG-AGT-3′). All polymerase chain reaction products were sequenced by an ABI Prism 377 DNA sequencer (Applied Biosystems, Foster City, CA, USA). To confirm the mutations, the exons were sequenced in the forward and reverse directions twice.
Results
Clinical Features
In the proband, high BP (160/120 mm Hg) had been detected in 1997 at the age of 15, during a routine physical examination, although no further intervention was performed. By November 2008, the symptoms of hemoptysis and fatigue had led the patient to undergo a medical examination, which revealed hypertension. The patient's serum potassium levels fluctuated between 2.40 and 3.50 mmol/L in the past 3 years before 2017, despite the oral administration of potassium chloride. His BP was also poorly controlled, ranging from 140 to 220 mm Hg (systolic) and from 100 to 150 mm Hg (diastolic), despite the administration of amlodipine, nifedipine, spirolactone, or losartan. He had also experienced dizziness in 2015 and 2016. In September 2017, the proband was admitted to Fuwai Hospital for further evaluation of hypertension and hypokalemia.
Biochemical examination showed a low serum potassium level of 3.21 mmol/L, low PRC (1.2; reference value, 2.8-39.9 μIU/mL), and normal PAC (4.3; reference value, 3.0-23.6 ng/ dL) in a standing position and significantly increased N-terminal prohormone of brain natriuretic peptide (826.3; reference value, lower than 150 pg/mL). Microalbuminuria and adrenocorticotrophic hormone levels were normal. Echocardiography, aortic CT, and cardiac magnetic resonance suggested right coronary valve prolapse, severe aortic valve insufficiency, and enlargement of the ascending aorta and left heart (left atrium anteroposterior diameter 49 mm and left ventricle end diastolic diameter 74 mm, in echocardiography). Because of these severe complications of LS, the proband had to receive an aortic valve replacement. After this procedure, coronary artery, renal, and adrenal abnormalities were ruled out by a CT scan.
Across 3 generations of the proband's family, 10 individuals among 20 participants had a history of hypertension. Most of them were early-onset hypertensive patients (7/10) younger than 30 years old, although the total age range was 3-50 years old. The early penetrance of LS was revealed in the proband's son (IV-10), in whom hypertension (150/130 mm Hg) emerged as 3 years of age and hypokalemia accompanied by fatigue emerged at 8 years of age. This boy had only been treated with potassium chloride, through which no significant improvement in fatigue or serum potassium level was achieved. The proband's father (II-11) had first become aware of his own hypertension due to suffering from severe epistaxis at the age of 29 years. Ten years later, he died of stroke with uncontrolled BP, despite the adminis- tration of amlodipine. Similarly, individual II-7 had also suffered from stroke because of hypertension at the age of 60 years. Three members of the family (II-7, III-16, and IV-10) were identified to have low serum potassium concentration. Suppressed PRC and PAC were noted in individuals III-15, IV-3, and IV-10. Only PAC was suppressed in individuals II-2, II-4, III-3, and IV-9 (Table 1) .
Genetic Analysis
As shown in Figure 2 , a heterozygous frameshift mutation in exon 13 of SCNN1B was detected in the proband. This involved the insertion of an additional guanine into a sequence of 3 adjacent guanines at codon 603 (c.1806dupG). This frameshift mutation transformed P603, Y604, P605, and S606 into A603, L604, P605, and Q606, as well as producing a new stop codon at position 607, deleting the last 34 amino acids of β-ENaC, including its PY motif. There were 9 affected patients with this causative mutation, while the other 11 participants lacked it in this family (Table 1 ). There was no mutation in sequenced exon 13 of SCNN1G in 20 participants in this family.
Tailored Medicine for Mutation Carriers
As a first treatment option, each hypertensive patient carrying the identified mutation was advised to adopt a healthy lifestyle, such as consuming a low-salt diet, quitting smoking and alcohol, and performing a moderate amount of exercise. In China, only compound amiloride containing amiloride (2.5 mg) and hydrochlorothiazide (25 mg) in each tablet are available. Among 9 mutation carriers diagnosed with LS, 8 accepted treatments with compound amiloride; the exception was individual IV-9, whose mother refused treatment for her. Initially, 8 LS patients took one compound amiloride every day for a month and then reexamined the BP and electrolytes (Table 1 ). Subjects III-3 and III-15 showed normokalemia, but their BP was still uncontrolled higher than 160/110 mm Hg. Hence, 2 tablets compound amiloride each day was adjusted for them. The rest of the 6 patients showed significant improvement in decreasing their BP and normalizing their potassium levels. After dose adjustment, subjects III-15 showed normal BP (125/96 mm Hg), while subjects III-3 also needed an angiotensin receptor blocker to keep BP lower than 140/100 mm Hg. 
Discussion
This study characterizes a frameshift mutation of the β subunit of ENaC, generating a premature stop codon at position 607 and deleting the remaining 34 amino acids. Specifically, genotype -phenotype analysis indicated the diagnosis of LS in a Chinese family with this mutation. Underestimation of the prevalence and variable phenotypes in LS remind us of the importance of genetic testing for patients with a suspected LS. Tailored medicine with ENaC inhibitor improved symptoms and prognosis for LS patients specifically and effectively.
With the progression of research on LS, the pathogenesis has been clarified. ENaC activity is enhanced with increasing probability of the channel being open and with the increasing number of channels expressed at the apical membrane of principal cells [16, 17] , leading to greater Na + reabsorption and plasma volume expansion, as well as a consequent increase in BP and decreases in renin and aldosterone secretion and hypokalemic metabolic alkalosis, resulting from a transepithelial lumen-negative voltage generated by increased Na + reabsorption, driving K + secretion across the apical membrane [8] . Both SCNN1B and SCNN1G mutations mainly influence the PY motif, which acts as the binding site of a specific ubiquitin ligase (Nedd4-2) and interacts with Nedd4-2 to catalyze the ubiquitination of ENaCs, resulting in their internalization and degradation [17, 18] . It is believed that the PY motif is essential for interaction with cytoskeletal proteins, endocytosis of the channel, or both [19] . SCNN1B and SCNN1G mutations associated with LS are incapable of combining with Nedd4-2 because of the deletion or alteration of the PY motif, but can activate ENaC [20, 21] .
Types of mutations in SCNN1B include frameshift, nonsense, and missense mutations [15] . To date, 24 SCNN1B mutations associated with LS have been identified. SCNN1B is thus regarded as the gene most commonly associated with LS pathogenicity. Most LS mutations in SCNN1B are missense mutations located in exon 13, which alter the PY motif [12] . Thus far, among all reported SCNN1B mutations, 9 frameshift mutations associated with LS have been identified. In 2017, Cui et al. [22] reported 2 isolated LS patients from different families who carried the SCNN1B mutation (c.1806_1807insG), although adequate genetic evidence on the mutated genes in their family members could not be obtained. The current study characterized this heterozygous mutation in SCNN1B (c.1806dupG) in a pedigree containing 9 LS patients. The proband's hypertensive father most probably carried the identified mutation, and that the proband inherited this condition from his father, since the proband's father (II-11) had died of stroke resulting from uncontrolled hypertension and his mother (II-12) had not.
Genotype was consistent with the phenotype in the aspect of resistant and early-onset hypertension. Nine carriers with identified pathogenic mutation had resistant hypertension and were diagnosed with LS. In addition, the age of onset of hypertension in 9 affected patients ranged from 3 to 48 years. Owing to early penetrance, the age of onset of LS is generally before 30 years [12] . Unusually, participant II-2 with LS was identified to have hypertension at the age of 48, which was the first time he had undergone a general physical examination. Hence, we supposed that he might have been hypertensive but without any symptoms before the diagnosis at this late age. On the other hand, there were also late-onset patients with LS [12, 23] .
However, as in other monogenic disorders, phenotypic variability is a notable characteristic of LS. Namely, the same mutation can result in different phenotypes, even in one family, including heterogeneity in the clinical manifestations [24] . For example, in the case of LS, hypokalemia may differ in its severity within the same family or may not be present at all [25] . In this family with LS, the serum potassium level varied among 9 carriers. Indi- viduals II-7, III-16, and IV-10 manifested typical hypokalemia with LS, while 4 carriers were detected with a normal serum potassium level because they had taken medicines for many years, namely, potassium chloride by III-3 and III-8 and antihypertensive agents (Ca 2+ channel blockers) by II-2 and II-4. In contrast, carriers III-15 and IV-9 were not hypokalemia altogether. This is consistent with the observation in the previous study in which the LS was identified that hypokalemia is not a universal finding among affected individuals [26] .
The ENaC inhibitors such as amiloride are safe and effective for controlling BP and correcting hypokalemia in LS patients. These drugs are known to act directly upon ENaC, as showed by their ability to extinguish sodium flux through the channel when expressed in Xenopus oocytes [19] . The dosage of compound amiloride varied among the LS patients in this family, indicating that they had different responses to amiloride [24] . However, uncontrolled BP was shown in III-3, even upon the administration of amiloride, hydrochlorothiazide, and angiotensin receptor blocker. Hence, besides medications, a healthy lifestyle is the basic option for treating LS, such as a low-salt diet and moderate exercise. Moreover, overstimulation of ENaC by metabolic abnormalities in obese individuals appears to be a probable cause of the hypertension [27] . Therefore, individual III-3 should consider losing weight for controlling BP due to a high body mass index (27.5 kg/m 2 ).
Genetic testing is an accurate and convenient tool for LS diagnosis. Previous studies suggested that genetic testing should be performed in patients with early-onset and lowrenin hypertension [12] or in early-onset hypertension patients after primary aldosteronism and renal and renovascular diseases have been ruled out [13] . In consideration of the variability in phenotypes and age of onset of hypertension, genetic diagnosis by sequencing exon 13 of SCNN1B and SCNN1G should be first considered for patients with hypertension resistant to conventional treatment. Of course, we should certainly pay particular attention to hypertensives with hypokalemia, with suppressed PRC or PAC and a notable family history of earlyonset hypertension. If there is no mutation in SCNN1B and SCNN1G in patients with clinical suspicion of LS, SCNN1A is worthy of sequencing lastly [14] .
Conclusion
We report a frameshift mutation in SCNN1B in a Chinese family with LS. This pathogenic mutation deletes the PY motif by generating a premature stop codon. This work enriches the range of genetic evidence for LS, indicating that genetic testing should be strongly recommended for patients with a clinical suspicion of LS, especially if there is a family history of hypertension, thereby guiding accurate diagnosis and early treatment facilitating a better prognosis.
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